May 07, 2020
CryoLife Initiates Enrollment in PROACT Xa Clinical Trial
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Jul 31, 2019
Global Anticoagulants (Xarelto, Eliquis, Pradaxa, Savaysa) Market 2019-2023
May 31, 2019
Anticoagulants Market, 2024 - Focus on Oral Anticoagulants & Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin)
Apr 18, 2019
Anticoagulants Reversal Drugs - Global Industry Outlook to 2026: The Approval of Blockbuster Drugs in Recent Years, and a Strong Pipeline, is Driving Growth
Mar 01, 2019
Anticoagulants - Global Market Outlook to 2024 with Profiles on 48 Players
Oct 11, 2018
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Sep 08, 2018
Aniara Diagnostica Launches http://www.DOACtesting.com Providing Specific Product Information For Direct Oral Anticoagulant Testing
Jun 14, 2018
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
May 24, 2018
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
Apr 30, 2018
Apixaban Market Extensive Analysis of Supply And Demand, Revenue, Risk and Share 2018-2025
Feb 13, 2018
GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
Jan 25, 2018
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
Jan 16, 2018
FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin
Dec 11, 2017
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Oct 30, 2017
FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Oct 05, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Aug 27, 2017
XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
Aug 21, 2017
New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study